These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 24002992)

  • 1. Usefulness of partial volume effect-corrected F-18 FDG PET/CT for predicting I-131 accumulation in the metastatic lymph nodes of patients with thyroid carcinoma.
    Maruoka Y; Abe K; Baba S; Isoda T; Kitamura Y; Mizoguchi N; Akamatsu G; Sasaki M; Honda H
    Ann Nucl Med; 2013 Dec; 27(10):873-9. PubMed ID: 24002992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can calcification predict 131I accumulation on metastatic lymph nodes in papillary thyroid carcinoma patients receiving 131I therapy? Comparison of CT, 131I WBS and 18F-FDG PET/CT.
    Kaneko K; Abe K; Baba S; Tanabe Y; Yabuuchi H; Hatakenaka M; Sasaki M; Honda H
    Eur Radiol; 2010 Feb; 20(2):477-83. PubMed ID: 19727757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic implication of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in patients with recurrent papillary thyroid cancer.
    Kang JH; Jung DW; Pak KJ; Kim IJ; Kim HJ; Cho JK; Shin SC; Wang SG; Lee BJ
    Head Neck; 2018 Jan; 40(1):94-102. PubMed ID: 29130586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preoperative Prediction of Cervical Lymph Node Metastasis Using Primary Tumor SUVmax on 18F-FDG PET/CT in Patients with Papillary Thyroid Carcinoma.
    Jung JH; Kim CY; Son SH; Kim DH; Jeong SY; Lee SW; Lee J; Ahn BC
    PLoS One; 2015; 10(12):e0144152. PubMed ID: 26636824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PROGNOSTIC VALUE OF LYMPH NODE UPTAKE ON PRETREATMENT F-18 FDG PET/CT IN PATIENTS WITH N1B PAPILLARY THYROID CARCINOMA.
    Lee CH; Lee SW; Son SH; Hong CM; Jeong JH; Jeong SY; Ahn BC; Lee J
    Endocr Pract; 2019 Aug; 25(8):787-793. PubMed ID: 31013158
    [No Abstract]   [Full Text] [Related]  

  • 6. Preablative Stimulated Thyroglobulin Levels Can Predict Malignant Potential and Therapeutic Responsiveness of Subcentimeter-Sized, 18F-fluorodeoxyglucose-Avid Cervical Lymph Nodes in Patients With Papillary Thyroid Cancer.
    Kwon SY; Kim J; Jung SH; Chong A; Song HC; Bom HS; Min JJ
    Clin Nucl Med; 2016 Jan; 41(1):e32-8. PubMed ID: 26164179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of central lymph node metastasis from papillary thyroid microcarcinoma by 18F-fluorodeoxyglucose PET/CT and ultrasonography.
    Byun BH; Jeong UG; Hong SP; Min JJ; Chong A; Song HC; Bom HS
    Ann Nucl Med; 2012 Jul; 26(6):471-7. PubMed ID: 22467230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic impact of incomplete surgical clearance of radioiodine sensitive local lymph node metastases diagnosed by post-operative (124)I-NaI-PET/CT in patients with papillary thyroid cancer.
    Sabet A; Binse I; Grafe H; Ezziddin S; Görges R; Poeppel TD; Bockisch A; Rosenbaum-Krumme SJ
    Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1988-94. PubMed ID: 27118127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of subcentimeter metastatic cervical lymph node by 18F-FDG PET/CT in patients with well-differentiated thyroid carcinoma and high serum thyroglobulin but negative 131I whole-body scan.
    Kunawudhi A; Pak-art R; Keelawat S; Tepmongkol S
    Clin Nucl Med; 2012 Jun; 37(6):561-7. PubMed ID: 22614187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics of primary papillary thyroid carcinoma with false-negative findings on initial (18)F-FDG PET/CT.
    Choi JW; Yoon YH; Yoon YH; Kim SM; Koo BS
    Ann Surg Oncol; 2011 May; 18(5):1306-11. PubMed ID: 21140231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-FDG-avid primary papillary thyroid carcinoma may not differ from FDG-avid papillary thyroid carcinoma.
    Kim MH; Ko SH; Bae JS; Lee SH; Jung CK; Lim DJ; Baek KH; Kim SH; Lee JM; Kang MI; Cha BY
    Thyroid; 2013 Nov; 23(11):1452-60. PubMed ID: 23688271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of residual lymph node metastases in high-risk papillary thyroid cancer patients receiving adjuvant I-131 therapy: the usefulness of F-18 FDG PET/CT.
    Kaneko K; Abe K; Baba S; Isoda T; Yabuuchi H; Sasaki M; Hatakenaka M; Honda H
    Clin Nucl Med; 2010 Jan; 35(1):6-11. PubMed ID: 20026964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo quantification of pulmonary inflammation in relation to emphysema severity via partial volume corrected (18)F-FDG-PET using computer-assisted analysis of diagnostic chest CT.
    Torigian DA; Dam V; Chen X; Saboury B; Udupa JK; Rashid A; Moghadam-Kia S; Alavi A
    Hell J Nucl Med; 2013; 16(1):12-8. PubMed ID: 23529388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relation Between F-18 FDG Uptake of PET/CT and BRAFV600E Mutation in Papillary Thyroid Cancer.
    Yoon S; An YS; Lee SJ; So EY; Kim JH; Chung YS; Yoon JK
    Medicine (Baltimore); 2015 Dec; 94(48):e2063. PubMed ID: 26632889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of preoperative 18F-FDG PET/CT in papillary thyroid cancer patients with a high metastatic lymph node ratio: a multicenter retrospective cohort study.
    Kwon SY; Choi EK; Kong EJ; Chong A; Ha JM; Chun KA; Cho IH; Bom HS; Min JJ; Kim J; Song HC; O JH; Kim SH
    Nucl Med Commun; 2017 May; 38(5):402-406. PubMed ID: 28306621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of 18F-Fluorodeoxyglucose Positron Emission Tomography in patients with suspected recurrence or metastatic differentiated thyroid carcinoma with elevated serum thyroglobulin and negative I-131 whole body scan.
    Trybek T; Kowalska A; Lesiak J; Młynarczyk J
    Nucl Med Rev Cent East Eur; 2014; 17(2):87-93. PubMed ID: 25088108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic value of metabolic tumor volume assessed by 18F-FDG PET/CT added to SUVmax for characterization of thyroid 18F-FDG incidentaloma.
    Kim BH; Kim SJ; Kim H; Jeon YK; Kim SS; Kim IJ; Kim YK
    Nucl Med Commun; 2013 Sep; 34(9):868-76. PubMed ID: 23797273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FDG-PET performed concurrently with initial I-131 ablation for differentiated thyroid cancer.
    Iwano S; Kato K; Ito S; Tsuchiya K; Naganawa S
    Ann Nucl Med; 2012 Apr; 26(3):207-13. PubMed ID: 22160654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluorodeoxyglucose-positron emission tomography scan-positive recurrent papillary thyroid cancer and the prognosis and implications for surgical management.
    Schreinemakers JM; Vriens MR; Munoz-Perez N; Guerrero MA; Suh I; Rinkes IH; Gosnell J; Shen WT; Clark OH; Duh QY
    World J Surg Oncol; 2012 Sep; 10():192. PubMed ID: 22985118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multimodal imaging with (18)F-FDG-PET/CT and (111)In-Octreotide SPECT in patients with metastatic medullary thyroid carcinoma.
    De Luca S; Fonti R; Camera L; Salvatore B; Faggiano A; Ciarmiello A; Segreto S; Colao A; Salvatore M; Del Vecchio S
    Ann Nucl Med; 2016 Apr; 30(3):234-41. PubMed ID: 26753628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.